Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H6I2
UPID:
SOX17_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H6I2
Background:
Transcription factor SOX-17 plays a pivotal role in embryonic development, including heart tube formation, vascular development, and fetal hematopoiesis. It functions as a transcription regulator, binding DNA to modulate transcriptional regulation via WNT3A and inhibiting Wnt signaling, crucial for normal development and maintenance of various biological systems.
Therapeutic significance:
SOX-17's involvement in Vesicoureteral reflux 3, a congenital anomaly of the kidney and urinary tract, underscores its potential as a therapeutic target. Understanding the role of Transcription factor SOX-17 could open doors to potential therapeutic strategies for managing this condition and preventing its progression to more severe renal diseases.